Home » Stocks » Sinovac Biotech

Sinovac Biotech Ltd. (SVA)

Stock Price: $6.47 USD 0.00 (0.00%)
Updated Aug 12, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 460.25M
Revenue (ttm) 224.89M
Net Income (ttm) 44.93M
Shares Out 98.90M
EPS (ttm) 0.28
PE Ratio 23.11
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 12, 2020
Last Price $6.47
Previous Close $6.47
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 6.47 - 6.47
Day's Volume 0
52-Week Range 6.47 - 6.47

More Stats

Market Cap 460.25M
Enterprise Value 274.37M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 98.90M
Float 43.17M
EPS (basic) 0.42
EPS (diluted) 0.28
FCF / Share 0.30
Dividend n/a
Dividend Yield n/a
Earnings Yield 4.33%
FCF Yield 6.19%
Payout Ratio n/a
Shares Short 201,325
Short Ratio n/a
Short % of Float 0.28%
Beta 0.10
PE Ratio 23.11
Forward PE n/a
P/FCF Ratio 16.17
PS Ratio 2.05
PB Ratio 1.82
Revenue 224.89M
Operating Income 68.56M
Net Income 44.93M
Free Cash Flow 28.47M
Net Cash 185.88M
Net Cash / Share 2.61
Gross Margin 94.97%
Operating Margin 30.49%
Profit Margin 16.20%
FCF Margin 12.66%
ROA 8.44%
ROE 16.95%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$6.00*
Low
6.00
Current: $6.47
High
6.00
Target: 6.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue24623017472.4367.4162.9371.7749.2256.8433.40
Revenue Growth7.14%31.72%140.71%7.44%7.12%-12.32%45.83%-13.42%70.18%-
Gross Profit21420515450.0449.0147.4651.2730.1235.7116.68
Operating Income68.5645.3245.420.503.701.899.95-21.153.37-13.36
Net Income44.9321.7825.81-0.60-1.42-1.527.44-14.85-0.84-8.51
Shares Outstanding94.8864.7357.0356.9556.3155.6855.3054.9354.6153.06
Earnings Per Share0.410.340.45-0.01-0.03-0.030.13-0.27-0.02-0.16
EPS Growth20.59%-24.44%--------
Operating Cash Flow39.077.9459.76-13.904.21-10.135.58-16.2513.94-14.28
Capital Expenditures-10.61-5.59-11.90-12.63-5.22-10.91-5.13-16.15-15.34-25.15
Free Cash Flow28.472.3547.86-26.53-1.01-21.040.44-32.41-1.40-39.43
Cash & Equivalents20617711665.4465.4691.2910791.24104103
Total Debt20.2713.9240.0743.0325.0051.7751.6937.7422.0320.49
Net Cash / Debt18616375.8922.4140.4639.5255.5653.5082.2582.60
Assets452370299211203239241209216214
Liabilities10077.8512281.6966.4296.8097.0579.3370.6166.60
Book Value294253151116122127129118130126
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Sinovac Biotech Ltd.
Country China
Employees 910
CEO Wei Dong Yin

Stock Information

Ticker Symbol SVA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SVA

Description

Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B, enterovirus 71 (EV71), seasonal influenza, H5N1 and H1N1 pandemic influenza, and mumps, as well as hand, foot, and mouth diseases. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also completed phase III clinical trials for varicella, pneumococcal polysaccharide, and Sabin inactivated polio vaccines. Further, it is developing rubella vaccine; Sabin-strain inactivated polio vaccine; Sars-coVv-2 (COVID-19) vaccine; and quadrivalent influenza vaccine. Sinovac Biotech Ltd. has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; Dynavax Technologies Corporation to develop a vaccine to prevent COVID-19; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. The company was founded in 1999 and is based in Beijing, the People's Republic of China.